QCG
RXRX icon

Quadrant Capital Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Quadrant Capital Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,114
Closed -$9.56K – 2306
2026
Q1 		$9.56K Sell
3,114
-39
-1% -$151 ﹤0.01% 2199
2025
Q4 		$12.9K Buy
+3,153
New +$15.6K ﹤0.01% 2137
2025
Q1 		– Sell
-143
Closed -$967 – 2831
2024
Q4 		$967 Hold
143
– – ﹤0.01% 2593
2024
Q3 		$943 Buy
+143
New +$1.02K ﹤0.01% 2602

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quadrant Capital Group's RXRX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 3,114 shares — an estimated $9.56K sold.

Quadrant Capital Group first reported a position in RXRX in Q3 2024 and held it in 4 quarters. The position peaked at $12.9K in Q4 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Quadrant Capital Group reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 3,114 Recursion Pharmaceuticals shares in Q2 2026, an estimated $9.56K.
  • Quadrant Capital Group first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Quadrant Capital Group's Recursion Pharmaceuticals position peaked at $12.9K in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.